Dr. Harri Jarvelainen has joined DrugCendR Inc. as the Chief Operating Officer (COO). He has more than 15 years of scientific, managerial and executive experience in biopharma industry – bringing small molecule drugs and biologicals from discovery to early development in multiple therapeutic areas. He has contributed to more than 30 first-in-man projects and has collaborated with and consulted for more than 50 biotechnology companies over the years. Erkki Ruoslahti, CEO of DrugCendR, stated: “We are pleased to have Dr. Jarvelainen in our team. He has provided a valuable service to our company in his previous role as a consultant role and will now be instrumental in the developing DrugCendR from a start-up into a biotech ready for the clinic. DrugCendR is currently completing the final preclinical, CMC and regulatory activities for its lead compound CEND-1 in preparation for a Phase I/IIa clinical study program. The trial is expected to initiate in early 2018.
DrugCendR Inc. Announces Appointment of Harri Jarvelainen, DVM, PhD, as Chief Operating Officer
July 30, 2017
For more information.
RECENT NEWS & RESOURCES
PRESS
ARCHIVES
- May 2020 (1)
- March 2020 (1)
- December 2019 (1)
- October 2019 (1)
- August 2019 (2)
- June 2019 (1)
- April 2019 (1)
- March 2019 (1)
- February 2019 (1)
- January 2019 (1)
- November 2018 (1)
- October 2018 (1)
- September 2018 (1)
- August 2018 (2)
- March 2018 (1)
- January 2018 (2)
- November 2017 (3)
- October 2017 (2)
- August 2017 (1)
- July 2017 (1)